Search Results

You are looking at 121 - 130 of 488 items for :

  • "adjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias, and Giovanni Casazza

micrometastases to the bone marrow: a long-term follow-up . Ann Oncol 2008 ; 19 : 2007 – 2011 . 13. Coleman R Thorpe H Cameron D . Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy—first safety data from the

Full access

Jordan M. Cloyd, Chengli Shen, Heena Santry, John Bridges, Mary Dillhoff, Aslam Ejaz, Timothy M. Pawlik, and Allan Tsung

recurrent disease. Although adjuvant chemotherapy improves survival for all patients with resected PDAC, 2 , 3 up to 50% of patients will not initiate postoperative chemotherapy, typically because of poor performance status after major surgery. 4 – 6 A

Full access

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Mark K. Buyyounouski, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Shilpa Gupta, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Timothy M. Kuzel, Clayton Lau, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Jue Wang, and Richard B. Wilder

site of relapse in patients managed with surveillance or adjuvant chemotherapy is the retroperitoneal nodes. Chest radiographs may be obtained as clinically indicated for years 1 to 5. The clinical trial TRISST (MRC TE24/Trial of Imaging and Schedule in

Full access

Nadeem R. Abu-Rustum and Yukio Sonoda

based on the Intergroup trial, 17 as opposed to postoperative chemotherapy, is an intriguing question. In 1996, Curtin et al. 18 reported on the clinical efficacy of adjuvant chemotherapy alone versus chemotherapy plus whole pelvic radiation therapy

Full access

Stephen B. Edge

: a study of the National Comprehensive Cancer Network . Ann Surg 2006 ; 243 : 241 – 249 . 14. Brewster AM Etzel C Zhou R . The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer

Full access

Prajnan Das, Norio Fukami, and Jaffer A. Ajani

– 11 . 30. Earle CC Maroun JA . Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials . Eur J Cancer 1999 ; 35 : 1059 – 1064 . 31. Janunger KG

Full access

Jacob Klapper and Thomas A. D’Amico

immune system, and the superior compliance with adjuvant chemotherapy. Although the extent of the lymph node dissection that can be accomplished via VATS has been a matter of debate, the literature suggests equivalency. Watanabe et al 15 compared

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Mohammad Jahanzeb, Krystyna Kiel, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Richard L. Theriault, Neal S. Topham, John H. Ward, Eric P. Winer, and Antonio C. Wolff

adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15 . J Natl Cancer Inst 2000 ; 92 : 1991 – 1998 . 39 Piccart MJ Di Leo A Hamilton A . HER2 a ‘predictive factor’ ready to use in

Full access

Yvonne H. Sada, Brandon G. Smaglo, Joy C. Tan, Hop S. Tran Cao, Benjamin L. Musher, and Nader N. Massarweh

.7% received only adjuvant chemotherapy, 18.4% received adjuvant chemotherapy and RT, and 13.9% received only adjuvant RT), whereas 12.8% of those treated with preoperative RT received adjuvant therapy (all of whom received only adjuvant chemotherapy). Table 1

Full access

Michaela A. Dinan, Lauren E. Wilson, and Shelby D. Reed

Background The introduction of genomic tests such as the Oncotype DX 21-gene recurrence score (RS) assay has allowed the omission of adjuvant chemotherapy for patients with estrogen receptor (ER)–positive, node-negative breast cancer who have a low